Abstract:

Objective To investigate the clinical features and drug resistance of pathogens in community-acquired pneumonia patients with Acinetobacter baumannii, and to strengthen clinicians' understanding for the pneumonia. Methods From January 2020 to June 2021, a total of 44 pneumonia patients with community-acquired Acinetobacter baumannii pneumonia from the Department of Respiratory Medicine, the Second Affiliated Hospital of Harbin Medical University were enrolled, bacterial identification and drug sensitive test were performed. The clinical data and outcomes were retrospectively analyzed. Results Community-acquired Acinetobacter baumannii pneumonia patients were often accompanied by cardio-cerebral disease and/or chronic lung disease, and their clinical manifestations mainly included cough, expectoration, dyspnea, and fever. In pulmonary CT, polymorphic changes, and bilateral lung involvement were more common. Acinetobacter baumannii exhibited varying degree of drug resistance, the resistance rate of beta-lactamases (carbapenems, piperacillin/tazobactam) and quinolones (ciprofloxacin) was higher, and the rate of carbapenems resistance was as high as 54.5%. Conclusion Patients with community-acquired pneumonia cased by Acinetobacter baumannii are mainly the aged who are usually suffering from cardio-cerebral disease and pulmonary disease in such situation. Furthermore, most of those patients are critically ill, but with a low mortality rate. Drug resistance of the pathogens discovered from those patients varies in different degree. All these characteristics needs to be concerned.

Key words: pneumonia, drug resistance, bacterial, acinetobacter baumannii, clinical characteristics